Avecho has announced the activation of three new clinical trial sites for our pivotal Phase III insomnia trial – two in Sydney and one on the Gold Coast.
This expansion significantly enhances the Company’s recruitment capabilities as it targets completion of dosing for approximately 210 subjects before conducting a planned interim analysis. The new sites maintain independent databases of insomnia patients, providing an immediate and valuable pool of prospective trial participants.
Following the exclusive licensing agreement with Sandoz in March 2025 – which included a substantial upfront payment of US $3M, with a further US $16M plus royalites committed in development milestones prior to commercial sales – the first strategic meeting was held last month to plan for future regulatory submission and commercial launch of our CBD product in Australia.
Avecho CEO, Dr Paul Gavin, said:"The licensing agreement with Sandoz has delivered the capital required to accelerate patient recruitment ahead of our interim analysis - a key milestone in the value development of the program. Our priority remains advancing the study to this critical inflection point as efficiently as possible."
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)